Muscle atrophy is a prevalent condition in today's societies, but many of the roles that mitochondria play in the process remain unclear. In a recent study, researchers investigated how muscle atrophy ...

As people grow older, their muscles begin to weaken, and they may start feeling the effects of muscular atrophy — a condition where the muscle wastes away. One University of Iowa researcher hopes to ...

Learn how to manage musculoskeletal pain in multiple sclerosis. Discover causes, symptoms, diagnosis, and effective treatment ...

A positive effect of nusinersen treatment on motor function in ambulant pediatric and adult spinal muscular atrophy (SMA) patients during a 38-month period has been demonstrated by an analysis of data ...

U.S. Food and Drug Administration has approved Novartis' gene therapy for a type of rare muscle disorder, the drugmaker said ...

Weakness in the legs can happen for a variety of reasons. These can include DOMS, spinal problems, neuropathy, ALS, stroke, myasthenia gravis, and Guillain-Barré syndrome (GBS). Weakness in the legs ...

You've likely heard of sciatica before. The shooting pain that runs down your lower back, buttocks and leg can disrupt your daily routine and linger for months. But if you've tried traditional ...

Oral risdiplam (Evrysdi, Genentech) started in the first 6 weeks of life let most infants with presymptomatic spinal muscular atrophy (SMA) reach motor milestones typical of healthy babies, results of ...

Scholar Rock's Apitegromab BLA received a CRL due to issues at Catalent Indiana's facility, unrelated to the drug itself. Scholar Rock is working with Catalent to address FDA observations and plans to ...

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.

A new clinical trial has revealed encouraging results for a muscle-targeting therapy aimed at improving motor function in children and adolescents with spinal muscular atrophy, according to a study ...